Our Take
The field is chasing consensus, not data: PD-1/VEGF bispecifics show stronger signals in liver cancer, yet the industry bet defaults to lung because that's where the crowded oncology money flows.
Why it matters
Drug development portfolios lock in for years. If pharma is deploying clinical and manufacturing resources toward the wrong indication, competitors who read the evidence clearly will capture the market faster and cheaper. This is a capital allocation mistake masquerading as strategy.
Do this week
Oncology investors and biopharma strategy teams: pull Phase 2 hepatocellular carcinoma data on PD-1/VEGF programs and compare efficacy readouts to lung cancer cohorts before your next portfolio review.
Pharma is crowding into lung cancer with PD-1/VEGF bispecifics
Multiple drugmakers are advancing PD-1/VEGF bispecific antibodies as oncology candidates, with the bulk of clinical investment and pipeline focus aimed at non-small-cell lung cancer (NSCLC). This concentration reflects both the large addressable market in lung cancer and the proven success of PD-1 checkpoint inhibitors in that setting. The strategy appears sound on the surface: combine two validated targets, attack a disease with existing standard-of-care alternatives, and capture the attention of oncologists already familiar with both pathways.
But the clinical record tells a different story. Evidence from early-stage trials suggests hepatocellular carcinoma (HCC), not lung cancer, produces the stronger and more consistent responses to this drug class. The liver cancer data shows more durable benefit, clearer dose-response curves, and fewer competing therapies in the space compared to the crowded lung cancer market where multiple checkpoint inhibitors, kinase inhibitors, and other combination approaches already compete.
Portfolio decisions made now lock in for five to ten years
Oncology development timelines are long. Once a company commits to a Phase 2 program in lung cancer, manufacturing scale-up, regulatory strategy, and clinical trial design all cascade downstream. Pivot costs grow with each year of investment. If the best clinical signal genuinely lives in liver cancer, companies pursuing lung cancer are not just making a sub-optimal choice; they are burning capital and opportunity window while competitors with clearer eyes on the data move first into a less defended market.
The misalignment likely reflects two forces: institutional momentum (lung cancer is where the oncology mindshare and payer agreements already exist) and herding behavior (if three competitors entered lung cancer, the fourth one follows). Neither force has much to do with where the drug actually works best.
Audit your indication strategy against the Phase 2 record, not the market size
If you are evaluating oncology partnerships, acquisitions, or in-licensing deals involving PD-1/VEGF bispecifics, disaggregate the clinical data by tumor type. Do not accept aggregated efficacy claims or the assumption that lung cancer is the logical starting point. Pull the hepatocellular carcinoma and NSCLC cohort data separately, compare response rates, progression-free survival, and safety profiles, and ask whether the indication choice reflects clinical merit or competitive herd behavior.
For internal portfolio teams: map where your competitors are placing their bets in this space. If they are locked into lung cancer and your data shows liver cancer advantage, that is a first-mover signal worth acting on, not a reason to match their move.